Christy M. Hebner

VIR Biotechnology (United States) — United States

Medicine · Health Sciences

21h-index4.1kcitations39works6.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(12), Hepatitis C virus research(8), COVID-19 Clinical Research Studies(6), Hepatitis B Virus Studies(5), HIV/AIDS drug development and treatment(5)

Publications39 total

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination
Nucleic Acids Research·2024· 5 citedOpen Access
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)
Clinical Infectious Diseases·2024· 18 citedOpen Access
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)
2024· 3 citedOpen Access
Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab
Future Virology·2024· 1 citedOpen Access
Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study
Future Virology·2023· 7 citedOpen Access
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice
Journal of Hepatology·2023· 46 citedOpen Access
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials
Journal of Hepatology·2023· 89 citedOpen Access
1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
Open Forum Infectious Diseases·2022· 7 citedOpen Access
The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice
2022· 2 citedOpen Access
Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2
2022Open Access
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Nature·2021· 213 citedOpen Access
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Nature·2021· 1.2k citedOpen Access
502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Open Forum Infectious Diseases·2021· 17 citedOpen Access
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Nature·2021· 565 citedOpen Access
Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
2021· 52 citedOpen Access
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
PubMed·2021· 17 citedOpen Access
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
2021· 21 citedOpen Access
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
2021· 250 citedOpen Access
1231. VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness
Open Forum Infectious Diseases·2020· 4 citedOpen Access
Potent LpxC Inhibitors with <i>In Vitro</i> Activity against Multidrug-Resistant Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy·2019· 59 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Hannah Kaiser(10), Julia di Iulio(9), Davide Corti(9), Florian A. Lempp(9), Andrea L. Cathcart(9), Elisabetta Cameroni(8), Laura E. Rosen(8), Fabrizia Zatta(8), Amalio Telenti(8), Herbert W. Virgin(8), Gyorgy Snell(8), Maria L. Agostini(8), Katja Culap(7), Dora Pinto(6), Anna De Marco(6), Colin Havenar‐Daughton(6), Leah Soriaga(6), Matteo Samuele Pizzuto(6), Jiayi Zhou(6), Martin Montiel-Ruiz(6)